Konjac glucomannan microcarriers: an application in the treatment of pulmonary tuberculosis
Tuberculosis remains one of the leading causes of death worldwide.1 The conventional therapy of this infection is based on the intake of a combination of several antitubercular drugs for a period that could reach 2 years.2 The prolonged treatment of tuberculosis has limited the therapeutic success,...
| Autor principal: | |
|---|---|
| Formato: | doctoralThesis |
| Idioma: | eng |
| Publicado em: |
2022
|
| Assuntos: | |
| Texto completo: | http://hdl.handle.net/10400.1/18446 |
| País: | Portugal |
| Oai: | oai:sapientia.ualg.pt:10400.1/18446 |